JP2013529077A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529077A5
JP2013529077A5 JP2013510352A JP2013510352A JP2013529077A5 JP 2013529077 A5 JP2013529077 A5 JP 2013529077A5 JP 2013510352 A JP2013510352 A JP 2013510352A JP 2013510352 A JP2013510352 A JP 2013510352A JP 2013529077 A5 JP2013529077 A5 JP 2013529077A5
Authority
JP
Japan
Prior art keywords
polypeptide
borrelia
nucleic acid
amino acid
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013510352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529077A (ja
JP6030052B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036525 external-priority patent/WO2011143617A1/en
Publication of JP2013529077A publication Critical patent/JP2013529077A/ja
Publication of JP2013529077A5 publication Critical patent/JP2013529077A5/ja
Application granted granted Critical
Publication of JP6030052B2 publication Critical patent/JP6030052B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013510352A 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法 Expired - Fee Related JP6030052B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
US61/334,901 2010-05-14
PCT/US2011/036525 WO2011143617A1 (en) 2010-05-14 2011-05-13 Chimeric ospa genes, proteins, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016126631A Division JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法

Publications (3)

Publication Number Publication Date
JP2013529077A JP2013529077A (ja) 2013-07-18
JP2013529077A5 true JP2013529077A5 (https=) 2014-06-26
JP6030052B2 JP6030052B2 (ja) 2016-11-24

Family

ID=44121257

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013510352A Expired - Fee Related JP6030052B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2013510354A Expired - Fee Related JP6227407B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126608A Withdrawn JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126631A Pending JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2018129896A Withdrawn JP2018150386A (ja) 2010-05-14 2018-07-09 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2020135857A Expired - Fee Related JP6965417B2 (ja) 2010-05-14 2020-08-11 Ｏｓｐａキメラおよびそのワクチンでの使用法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2013510354A Expired - Fee Related JP6227407B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126608A Withdrawn JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126631A Pending JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2018129896A Withdrawn JP2018150386A (ja) 2010-05-14 2018-07-09 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2020135857A Expired - Fee Related JP6965417B2 (ja) 2010-05-14 2020-08-11 Ｏｓｐａキメラおよびそのワクチンでの使用法

Country Status (13)

Country Link
US (6) US8623375B2 (https=)
EP (4) EP2569009B1 (https=)
JP (6) JP6030052B2 (https=)
KR (7) KR20130062954A (https=)
CN (3) CN103108652B (https=)
AU (2) AU2011252844B2 (https=)
BR (2) BR112012027315B1 (https=)
CA (2) CA2799181C (https=)
MX (3) MX340739B (https=)
PL (2) PL2569008T3 (https=)
RU (2) RU2583289C2 (https=)
SI (2) SI2569008T1 (https=)
WO (2) WO2011143623A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252844B2 (en) 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
WO2012054786A1 (en) 2010-10-20 2012-04-26 Playspan Inc. Flexible monetization service apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
WO2013090611A2 (en) * 2011-12-13 2013-06-20 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
AU2013293448A1 (en) * 2012-07-27 2015-02-05 Baxalta GmbH Compositions comprising chimeric OspA molecules and methods of use thereof
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US20140296139A1 (en) * 2013-03-15 2014-10-02 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
US20160213766A1 (en) * 2013-09-23 2016-07-28 Ventria Bioscience, Inc. OspA Fusion Protein for Vaccination against Lyme Disease
HUE043779T2 (hu) 2014-01-09 2019-09-30 Valneva Austria Gmbh Az OspA mutáns fragmensei, valamint az ezzel kapcsolatos módszerek és alkalmazások
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
EP4108256A1 (en) * 2014-08-11 2022-12-28 University of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
JP6603400B2 (ja) * 2015-08-14 2019-11-06 テレフオンアクチーボラゲット エルエム エリクソン（パブル） パケットデータネットワーク接続を管理するためのノード及び方法
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
KR20210018205A (ko) * 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
CA3174599A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4262860A4 (en) 2020-12-17 2025-11-12 Idexx Lab Inc DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER
US20240368654A1 (en) * 2021-06-07 2024-11-07 University Of Massachusetts Apparatus and method for continuous production of rna
CN119173446A (zh) 2022-03-08 2024-12-20 赤盾医疗有限公司 机器人药物制备系统中的流体转移站
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2084413A1 (en) 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FI933580A7 (fi) 1991-02-15 1993-10-13 Uab Research Foundation Pneumokokkiproteiinin rakennegeeni
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6113914A (en) * 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
AU8127494A (en) 1993-11-01 1995-05-23 Associated Universities, Inc. Chimeric proteins comprising borrelia polypeptides: uses therefor
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
EP0880360B1 (en) 1996-02-12 2002-10-09 Cobra Therapeutics Limited Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6660274B2 (en) * 1997-06-30 2003-12-09 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
AU2001281145A1 (en) * 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Recombinant constructs of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
ATE381575T1 (de) * 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
WO2004089969A2 (en) 2003-04-02 2004-10-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
BRPI0409459A (pt) * 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
MY148656A (en) * 2004-03-24 2013-05-15 Merck Sharp & Dohme Optimized expression of hpv 52 l1 in yeast.
US8821893B2 (en) 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
JP5390189B2 (ja) * 2005-11-29 2014-01-15 ヴァージニア コモンウェルス ユニバーシティ 多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原
JP2010503384A (ja) 2006-09-15 2010-02-04 インターセル アーゲー ボレリア（Ｂｏｒｒｅｌｉａ）抗原
ATE496935T1 (de) 2007-02-22 2011-02-15 Baxter Int Verfahren zur aufreinigung hydrophober proteine
CA2690708A1 (en) * 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
KR101686942B1 (ko) * 2008-01-11 2016-12-28 이노비오 파마수티컬즈, 인크. 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신
US20110105355A1 (en) 2008-04-22 2011-05-05 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
AU2011252844B2 (en) * 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
AU2013293448A1 (en) * 2012-07-27 2015-02-05 Baxalta GmbH Compositions comprising chimeric OspA molecules and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2013529077A5 (https=)
JP2013529078A5 (https=)
RU2012153972A (ru) Химерные гены ospa, белки и способы их применения
US20260070950A1 (en) Mutant fragments of ospa and methods and uses relating thereto
JP2016526026A (ja) 低免疫原性タンパク質に対するエピトープワクチンおよびその製造方法と使用
HRP20170094T1 (hr) Imunogeni pripravak
EP3279217A1 (en) Streptococcus pneumoniae protein antigen, and preparation method and use thereof
US20210101962A1 (en) Mosaic Chimeric Viral Vaccine Particle
EP3863666A2 (en) Treatment and prevention of malaria based on the antigen pfrh5 and antibodies against the same
CN107033226B (zh) 一种小反刍兽疫病毒f蛋白抗原表位肽及其确定、制备方法和应用
JP2023540778A (ja) Ａｃｅ２結合力が減少したコロナウイルス由来の受容体結合ドメイン変異体及びこれを含むワクチン組成物
TWI782542B (zh) 一種鞭毛蛋白的重組蛋白及其用途
CN103421817B (zh) 人工合成的猪繁殖与呼吸综合征病毒多表位基因及应用
CN102219858A (zh) 微小隐孢子虫ctl多表位基因和融合蛋白及其应用
CN101880328B (zh) 微小隐孢子虫Th多表位基因和融合蛋白及其应用
CN105254719B (zh) 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗
CN102276725A (zh) 隐孢子虫CTL和Th混合多表位基因和融合蛋白及应用
RU2005101744A (ru) Последовательность днк и получение аллергена пыльцы трав ph1 p4 с помощью рекомбинантных способов
CN107034198A (zh) 一种嵌合诺如病毒p颗粒及其制备和应用
CN102847167B (zh) 一种预防奶牛乳腺炎的改进型增效核酸疫苗的构建
최훈철 Development of recombinant vaccine against Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)
CN105713096A (zh) 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
CN105384800A (zh) 金黄色葡萄球菌taf融合蛋白制备方法及其应用
CN110938150A (zh) E型肉毒毒素重组hn-l抗原的制备方法及其应用
HK40016829A (en) Mutant fragments of ospa and methods and uses relating thereto